Clinical Trial Update: Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase II trial evaluating GM-CSF in combination with mitoxantrone for hormone-refractory prostate cancer was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Novantrone (mitoxantrone)
• sargramostim (sargramostim)

Snippet

Sponsor: Stanford University | Conditions: Prostatic Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2017-11-29